Isu tinoshandisa yekucheka-kumucheto sainzi kugadzira hunyanzvi hwekurapa hunovandudza hupenyu hweavo vanorwara negomarara, kurwadziwa kusingagone uye COVID-19.
kenza yakasiyana-siyana, inoshanduka-shanduka, inogara ichichinja uye inenge isingaonekwe kune immune system. Maitiro edu ekurapa cancer anobva pakutenda kuti varwere vanozoda multimodal, multipronged nzira - yakanangana neseti imwe chete kana dzakasiyana-siyana dzenharembozha uye kurwisa avo vari pamativi akati wandei - panguva imwe chete kana sequentially, kazhinji uye zvisingaite.
Maitiro edu ekurwisa gomarara anoitwa kuti agoneke neyakasarudzika immuno-oncology ("IO") portfolio, ine huwandu hwakawanda hwezvinhu zvitsva uye synergistic assets, senge raibhurari yakafara yekurwisa vanhu ("G-MAB™") inogona. kushandiswa kwavo vega kana kuisirwa nzira dzekunangana negomarara dzinosanganisira:
Zvinhu izvi zvinotsigirwa neinovandudza lymphatic kunanga mudziyo (Sofusa®) yakagadzirirwa kuendesa masoja ekudzivirira chirwere mu lymphatic system, uko maseru edziviriro anodzidziswa kurwisa cancer.
Isu takagadzira masoja ekudzivirira chirwere evanhu achipesana nezvinangwa zvakawanda zvakakosha mukurapa cancer, zvinosanganisira PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, uye zvimwe zvakawanda zvinangwa, zviri pamatanho akasiyana ebudiriro. Zvirongwa zvedu zveCAR-T zvinosanganisira danho rekiriniki CD38 CAR T. Mishonga inosanganisa nzira dziri mu preclinical nhanho yekuongorora myeloma yakawanda, kenza yemapapu, uye mamwe magomarara evakuru nevana.
- CAR T (Chimeric Antigen Receptor - T Cells) kurapa kunogadzirisa murwere T-seli kuuraya bundu ravo.
- DAR T (Dimeric Antigen Receptor - T Cells) kurapa iyo inoshandura T-masero eanopa ane hutano kuti ashande kune chero bundu remurwere, zvichibvumira "kubva pasherufu" kurapwa kwebundu remurwere.
- Antibody-Drug Conjugates ("ADCs"), uye
- Oncolytic Virus zvirongwa (Seprehvir™, Seprehvec™)
"Yedu yakasarudzika portfolio yeIO papuratifomu midziyo haina makwikwi muindasitiri. Inosanganisira immune checkpoint inhibitors, bispecific antibodies, antibody-drug conjugates (ADCs) pamwe nechimeric antigen receptor (CAR) uye dimeric antigen receptor (DAR) based cellular therapies, uye nguva pfupi yadarika takawedzera oncolytic virus (Seprehvir™, Seprehvec). ™). Chinhu chimwe nechimwe chinoratidza vimbiso huru; tikaiswa pamwechete tinonzwa vane mukana wekupfuura nemumatambudziko akaomarara egomarara "
– Dr. Henry Ji, CEO
Kuzvipira kwedu kuvandudza hupenyu hwevarwere vane izvo zvino zvinofungidzirwa sekurwadziwa kusingagoneki kunoratidzwawo nekuedza kwedu kusingagumi kukudziridza yekutanga-in-class (TRPV1 agonist) isiri-opioid duku molecule, Resiniferatoxin ("RTX").
Resiniferatoxin ine mukana wekushandura zvakanyanya nzira yekudzivirira marwadzo mune zvakasiyana-siyana zviratidzo, nekuda kwesimba uye rinogara kwenguva refu nehutungamiri humwe chete asiwo nekuda kwezvibatsiro zvezvinyorwa zvayo zvisiri zveopioid.
RTX iri kupedzisa pre-pivotal miedzo muzviratidzo zvevanhu senge osteoarthritis uye kupera kwekenza yehupenyu kurwadziwa, nezvidzidzo zvakakosha zvekunyoresa zvakarongwa kutanga hafu yechipiri 2020.
RTX iri zvakare mumiyedzo yakakosha yekushandisa mune imbwa dzinofambidzana dzakaoma kubata marwadzo egokora reArthritic. Sezvo mhuka dzinovaraidza dziri chikamu chemhuri, maitiro edu ekugadzira magadzirirwo ekugadzirisa marwadzo anoitirwa kubatanidza mamwe marudzi atinoda!